Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases

被引:67
|
作者
Sun, Jong-Mu [1 ]
Ahn, Jin Seok [1 ]
Lee, Soohyeon [1 ]
Kim, Jung A. [1 ]
Lee, Jeeyun [1 ]
Park, Yeon Hee [1 ]
Park, Hee Chul [2 ]
Ahn, Myung-Ju [1 ]
Ahn, Yong Chan [2 ]
Park, Keunchil [1 ]
机构
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol,Dept Med, Seoul 135710, South Korea
[2] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Radiat Oncol, Seoul 135710, South Korea
关键词
Non-small cell lung cancer; Fracture; Spinal cord compression; Skeletal-related event; Predictive factor; RECEPTOR TYROSINE KINASE; PLACEBO-CONTROLLED TRIAL; EGF-LIKE LIGANDS; ZOLEDRONIC ACID; BREAST-CANCER; ZD1839; IRESSA; SOLID TUMORS; DOUBLE-BLIND; NUDE-MICE; PHASE-III;
D O I
10.1016/j.lungcan.2010.04.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Skeletal-related events (SREs) cause significant pain and morbidity to many non-small cell lung cancer (NSCLC) patients. We try to evaluate the predictive factor of SREs in NSCLC patients with bone metastases. Patients and methods: We retrospectively examined the medical charts of 273 patients diagnosed with bone metastases secondary to NSCLC. The predictive factor of SREs was analyzed using the first-event analyses and a survival-adjusted multiple-event analysis. Results: Out of 273 patients with bone metastases, 171 (62.6%) had at least one SRE and 46 of these experienced multiple SREs. In the first-event analyses, a larger proportion of ever-smokers have experienced the SRE compared with never-smokers (odds ratio, 2.80: 95% CI, 1.32-6.00). In addition, ever-smokers (hazard ratio [HR], 1.75; 95% Cl, 1.05-2.92), patients without history of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) therapy (HR, 2.12; 95% CI, 1.49-3.00) and patients with histology of nonadenocarcinoma (HR, 1.59; 95% Cl, 1.14-2.22) had a shorter median time from bone metastasis to first SRE. In a survival-adjusted multiple-event analysis, clinical characteristics such as ever-smoking, nonadenocarcinoma, poor performance status (ECOG >= 2), and no history of EGFR TKI therapy were independent risk factor of development of SRE throughout the course of disease. Conclusion: Our data indicate that patients with characteristics such as ever-smoking, nonadenocarcinoma, poor performance status, and no history of treatment with EGFR TKI are more likely to have SRE, so more vigilant surveillance and prevention should be considered to these patients. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:89 / 93
页数:5
相关论文
共 50 条
  • [31] Positive effects of zoledronate on skeletal-related events in patients with renal cell cancer and bone metastases EDITORIAL COMMENT
    Tu, Shi-Ming
    Chen, Adrienne H.
    CANADIAN JOURNAL OF UROLOGY, 2012, 19 (03) : 6268 - 6268
  • [32] Healthcare utilization and costs associated with skeletal-related events in prostate cancer patients with bone metastases
    Hagiwara, M.
    Delea, T. E.
    Saville, M. W.
    Chung, K.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2013, 16 (01) : 23 - 27
  • [33] Clinicopathological Factors in Non-Small Cell Lung Cancer Patients with Bone Metastases
    Ulas, Arife
    Bilici, Ahmet
    Durnali, Ayse
    Tokluoglu, Saadet
    Akinci, Sema
    Silay, Kamile
    Oksuzoglu, Berna
    Alkis, Necati
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S535 - S535
  • [34] Healthcare utilization and costs associated with skeletal-related events in prostate cancer patients with bone metastases
    M Hagiwara
    T E Delea
    M W Saville
    K Chung
    Prostate Cancer and Prostatic Diseases, 2013, 16 : 23 - 27
  • [35] The impact of skeletal-related events on pain interference in patients with advanced breast cancer and bone metastases
    Fallowfield, Lesley
    Patrick, Donald L.
    Von Moos, Roger
    Cleeland, Charles S.
    Zhou, Ying
    Balakumaran, Arun
    Qian, Yi
    CANCER RESEARCH, 2015, 75
  • [36] Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases
    von Moos, Roger
    Body, Jean-Jacques
    Egerdie, Blair
    Stopeck, Alison
    Brown, Janet
    Fallowfield, Lesley
    Patrick, Donald L.
    Cleeland, Charles
    Damyanov, Danail
    Salvador Palazzo, Felipe
    Marx, Gavin
    Zhou, Ying
    Braun, Ada
    Balakumaran, Arun
    Qian, Yi
    SUPPORTIVE CARE IN CANCER, 2016, 24 (03) : 1327 - 1337
  • [37] Skeletal morbidity and zoledronic acid benefits in patients with bone metastases from non-small cell lung cancer
    Harper, Peter
    Hirsh, Vira
    Cook, Richard
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S435 - S435
  • [38] Skeletal-related events (SREs) in breast cancer patients with bone metastases treated in the nontrial setting
    Trinkaus, Mateya
    Simmons, Christine
    Myers, Jeff
    Dranatisaris, George
    Clemons, Mark
    SUPPORTIVE CARE IN CANCER, 2010, 18 (02) : 197 - 203
  • [39] Skeletal-related events (SREs) in breast cancer patients with bone metastases treated in the nontrial setting
    Mateya Trinkaus
    Christine Simmons
    Jeff Myers
    George Dranatisaris
    Mark Clemons
    Supportive Care in Cancer, 2010, 18 : 197 - 203
  • [40] Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases
    Roger von Moos
    Jean-Jacques Body
    Blair Egerdie
    Alison Stopeck
    Janet Brown
    Lesley Fallowfield
    Donald L. Patrick
    Charles Cleeland
    Danail Damyanov
    Felipe Salvador Palazzo
    Gavin Marx
    Ying Zhou
    Ada Braun
    Arun Balakumaran
    Yi Qian
    Supportive Care in Cancer, 2016, 24 : 1327 - 1337